Hydroxychloroquine modulates elevated expression of S100 proteins in systemic lupus erythematosus
Objectives We investigated the effect of hydroxychloroquine (HCQ) on S100A8 and S100A9 serum levels in systemic lupus erythematosus (SLE) patients with low disease activity receiving immunosuppressants. Methods SELENA-SLEDAI, Cutaneous Lupus Erythematous Disease Area and Severity Index (CLASI) and s...
Gespeichert in:
| Veröffentlicht in: | Lupus 2019-06, Vol.28 (7), p.826-833 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 833 |
|---|---|
| container_issue | 7 |
| container_start_page | 826 |
| container_title | Lupus |
| container_volume | 28 |
| creator | Wakiya, R Kameda, T Ueeda, K Nakashima, S Shimada, H Mansour, M F Kato, M Miyagi, T Miyatake, N Kadowaki, N Dobashi, H |
| description | Objectives
We investigated the effect of hydroxychloroquine (HCQ) on S100A8 and S100A9 serum levels in systemic lupus erythematosus (SLE) patients with low disease activity receiving immunosuppressants.
Methods
SELENA-SLEDAI, Cutaneous Lupus Erythematous Disease Area and Severity Index (CLASI) and serum levels of complement factors, anti-dsDNA antibodies, and white blood cell, lymphocyte, and platelet counts were used to evaluate disease activity, cutaneous disease activity, and immunological activity, respectively. Serum S100A8 and S100A9 were measured at HCQ administration and after 3 or 6 months using ELISA.
Results
S100A8 and S100A9 serum levels were elevated at baseline and the magnitude of decrease from baseline at 3 and 6 months after HCQ administration was greater in patients with renal involvement than in those without (baseline: S100A8, p = 0.034; S100A9, p = 0.0084; decrease: S100A8, p = 0.049; S100A9, p = 0.023). S100 modulation was observed in patients with (n = 17; S100A8, p = 0.0011; S100A9, p = 0.0002) and without renal involvement (n = 20; S100A8, p = 0.0056; S100A9, p = 0.0012), and was more apparent in patients with improved CLASI activity scores (improved: S100A8, p = 0.013; S100A9, p = 0.0032; unimproved: S100A8, p = 0.055; S100A9, p = 0.055). No associations were observed for immunological biomarkers.
Conclusion
HCQ may improve organ involvement in SLE by modulating S100 protein levels, especially in patients with renal or skin involvement. |
| doi_str_mv | 10.1177/0961203319846391 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2231939211</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0961203319846391</sage_id><sourcerecordid>2231939211</sourcerecordid><originalsourceid>FETCH-LOGICAL-c449t-2e82d4e1d0515a52905f7d20e692791dc7d9abb2c701f9f4d0e24250a4aabc73</originalsourceid><addsrcrecordid>eNp1kM1L7TAQxYM80evH3pUE3sZNdSb9yM1S5D0VBBe6L7nNVCtt05dpxf73plz1gSAEJmR-52TmCHGCcI6o9QWYAhWkKZp1VqQGd8QKM62T-K5-idXSTpb-vjhgfgGASBZ7Yj9FKNbxrIS9mV3wb3P13Prg_01NT7LzbmrtSCyppdd4cZLehkDMje-lr-UDAsgh-JGanmXTS555pK6pZDsNU5SFeXymzo6eJz4Su7VtmY4_6qF4_Pvn8eomubu_vr26vEuqLDNjomitXEboIMfc5spAXmungAqjtEFXaWfsZqMqDVibOnNAKlM52MzaTaXTQ3G2tR2WNYjHsmu4ora1PfmJS6Xi7qlRiBH9_Q198VPo43ALZTDNc5VGCrZUFTxzoLocQtPZMJcI5ZJ--T39KDn9MJ42HbkvwWfcEUi2ANsn-v_rj4bvuh2M_g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2239135523</pqid></control><display><type>article</type><title>Hydroxychloroquine modulates elevated expression of S100 proteins in systemic lupus erythematosus</title><source>MEDLINE</source><source>SAGE Complete</source><creator>Wakiya, R ; Kameda, T ; Ueeda, K ; Nakashima, S ; Shimada, H ; Mansour, M F ; Kato, M ; Miyagi, T ; Miyatake, N ; Kadowaki, N ; Dobashi, H</creator><creatorcontrib>Wakiya, R ; Kameda, T ; Ueeda, K ; Nakashima, S ; Shimada, H ; Mansour, M F ; Kato, M ; Miyagi, T ; Miyatake, N ; Kadowaki, N ; Dobashi, H</creatorcontrib><description>Objectives
We investigated the effect of hydroxychloroquine (HCQ) on S100A8 and S100A9 serum levels in systemic lupus erythematosus (SLE) patients with low disease activity receiving immunosuppressants.
Methods
SELENA-SLEDAI, Cutaneous Lupus Erythematous Disease Area and Severity Index (CLASI) and serum levels of complement factors, anti-dsDNA antibodies, and white blood cell, lymphocyte, and platelet counts were used to evaluate disease activity, cutaneous disease activity, and immunological activity, respectively. Serum S100A8 and S100A9 were measured at HCQ administration and after 3 or 6 months using ELISA.
Results
S100A8 and S100A9 serum levels were elevated at baseline and the magnitude of decrease from baseline at 3 and 6 months after HCQ administration was greater in patients with renal involvement than in those without (baseline: S100A8, p = 0.034; S100A9, p = 0.0084; decrease: S100A8, p = 0.049; S100A9, p = 0.023). S100 modulation was observed in patients with (n = 17; S100A8, p = 0.0011; S100A9, p = 0.0002) and without renal involvement (n = 20; S100A8, p = 0.0056; S100A9, p = 0.0012), and was more apparent in patients with improved CLASI activity scores (improved: S100A8, p = 0.013; S100A9, p = 0.0032; unimproved: S100A8, p = 0.055; S100A9, p = 0.055). No associations were observed for immunological biomarkers.
Conclusion
HCQ may improve organ involvement in SLE by modulating S100 protein levels, especially in patients with renal or skin involvement.</description><identifier>ISSN: 0961-2033</identifier><identifier>EISSN: 1477-0962</identifier><identifier>DOI: 10.1177/0961203319846391</identifier><identifier>PMID: 31068068</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Anti-DNA antibodies ; Antirheumatic Agents - therapeutic use ; Biomarkers - blood ; Calgranulin A - blood ; Calgranulin B - blood ; Enzyme-linked immunosorbent assay ; Female ; Humans ; Hydroxychloroquine ; Hydroxychloroquine - therapeutic use ; Immunology ; Immunosuppressive agents ; Kidneys ; Lupus ; Lupus Erythematosus, Cutaneous - blood ; Lupus Erythematosus, Cutaneous - drug therapy ; Lupus Erythematosus, Systemic - blood ; Lupus Erythematosus, Systemic - drug therapy ; Lupus Nephritis - blood ; Lupus Nephritis - drug therapy ; Male ; Middle Aged ; Retrospective Studies ; S100 protein ; Serum levels ; Severity of Illness Index ; Skin ; Systemic lupus erythematosus ; Treatment Outcome</subject><ispartof>Lupus, 2019-06, Vol.28 (7), p.826-833</ispartof><rights>The Author(s) 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c449t-2e82d4e1d0515a52905f7d20e692791dc7d9abb2c701f9f4d0e24250a4aabc73</citedby><cites>FETCH-LOGICAL-c449t-2e82d4e1d0515a52905f7d20e692791dc7d9abb2c701f9f4d0e24250a4aabc73</cites><orcidid>0000-0003-1998-548X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0961203319846391$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0961203319846391$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31068068$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wakiya, R</creatorcontrib><creatorcontrib>Kameda, T</creatorcontrib><creatorcontrib>Ueeda, K</creatorcontrib><creatorcontrib>Nakashima, S</creatorcontrib><creatorcontrib>Shimada, H</creatorcontrib><creatorcontrib>Mansour, M F</creatorcontrib><creatorcontrib>Kato, M</creatorcontrib><creatorcontrib>Miyagi, T</creatorcontrib><creatorcontrib>Miyatake, N</creatorcontrib><creatorcontrib>Kadowaki, N</creatorcontrib><creatorcontrib>Dobashi, H</creatorcontrib><title>Hydroxychloroquine modulates elevated expression of S100 proteins in systemic lupus erythematosus</title><title>Lupus</title><addtitle>Lupus</addtitle><description>Objectives
We investigated the effect of hydroxychloroquine (HCQ) on S100A8 and S100A9 serum levels in systemic lupus erythematosus (SLE) patients with low disease activity receiving immunosuppressants.
Methods
SELENA-SLEDAI, Cutaneous Lupus Erythematous Disease Area and Severity Index (CLASI) and serum levels of complement factors, anti-dsDNA antibodies, and white blood cell, lymphocyte, and platelet counts were used to evaluate disease activity, cutaneous disease activity, and immunological activity, respectively. Serum S100A8 and S100A9 were measured at HCQ administration and after 3 or 6 months using ELISA.
Results
S100A8 and S100A9 serum levels were elevated at baseline and the magnitude of decrease from baseline at 3 and 6 months after HCQ administration was greater in patients with renal involvement than in those without (baseline: S100A8, p = 0.034; S100A9, p = 0.0084; decrease: S100A8, p = 0.049; S100A9, p = 0.023). S100 modulation was observed in patients with (n = 17; S100A8, p = 0.0011; S100A9, p = 0.0002) and without renal involvement (n = 20; S100A8, p = 0.0056; S100A9, p = 0.0012), and was more apparent in patients with improved CLASI activity scores (improved: S100A8, p = 0.013; S100A9, p = 0.0032; unimproved: S100A8, p = 0.055; S100A9, p = 0.055). No associations were observed for immunological biomarkers.
Conclusion
HCQ may improve organ involvement in SLE by modulating S100 protein levels, especially in patients with renal or skin involvement.</description><subject>Adult</subject><subject>Anti-DNA antibodies</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Biomarkers - blood</subject><subject>Calgranulin A - blood</subject><subject>Calgranulin B - blood</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Female</subject><subject>Humans</subject><subject>Hydroxychloroquine</subject><subject>Hydroxychloroquine - therapeutic use</subject><subject>Immunology</subject><subject>Immunosuppressive agents</subject><subject>Kidneys</subject><subject>Lupus</subject><subject>Lupus Erythematosus, Cutaneous - blood</subject><subject>Lupus Erythematosus, Cutaneous - drug therapy</subject><subject>Lupus Erythematosus, Systemic - blood</subject><subject>Lupus Erythematosus, Systemic - drug therapy</subject><subject>Lupus Nephritis - blood</subject><subject>Lupus Nephritis - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Retrospective Studies</subject><subject>S100 protein</subject><subject>Serum levels</subject><subject>Severity of Illness Index</subject><subject>Skin</subject><subject>Systemic lupus erythematosus</subject><subject>Treatment Outcome</subject><issn>0961-2033</issn><issn>1477-0962</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1L7TAQxYM80evH3pUE3sZNdSb9yM1S5D0VBBe6L7nNVCtt05dpxf73plz1gSAEJmR-52TmCHGCcI6o9QWYAhWkKZp1VqQGd8QKM62T-K5-idXSTpb-vjhgfgGASBZ7Yj9FKNbxrIS9mV3wb3P13Prg_01NT7LzbmrtSCyppdd4cZLehkDMje-lr-UDAsgh-JGanmXTS555pK6pZDsNU5SFeXymzo6eJz4Su7VtmY4_6qF4_Pvn8eomubu_vr26vEuqLDNjomitXEboIMfc5spAXmungAqjtEFXaWfsZqMqDVibOnNAKlM52MzaTaXTQ3G2tR2WNYjHsmu4ora1PfmJS6Xi7qlRiBH9_Q198VPo43ALZTDNc5VGCrZUFTxzoLocQtPZMJcI5ZJ--T39KDn9MJ42HbkvwWfcEUi2ANsn-v_rj4bvuh2M_g</recordid><startdate>20190601</startdate><enddate>20190601</enddate><creator>Wakiya, R</creator><creator>Kameda, T</creator><creator>Ueeda, K</creator><creator>Nakashima, S</creator><creator>Shimada, H</creator><creator>Mansour, M F</creator><creator>Kato, M</creator><creator>Miyagi, T</creator><creator>Miyatake, N</creator><creator>Kadowaki, N</creator><creator>Dobashi, H</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1998-548X</orcidid></search><sort><creationdate>20190601</creationdate><title>Hydroxychloroquine modulates elevated expression of S100 proteins in systemic lupus erythematosus</title><author>Wakiya, R ; Kameda, T ; Ueeda, K ; Nakashima, S ; Shimada, H ; Mansour, M F ; Kato, M ; Miyagi, T ; Miyatake, N ; Kadowaki, N ; Dobashi, H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c449t-2e82d4e1d0515a52905f7d20e692791dc7d9abb2c701f9f4d0e24250a4aabc73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Anti-DNA antibodies</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Biomarkers - blood</topic><topic>Calgranulin A - blood</topic><topic>Calgranulin B - blood</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Female</topic><topic>Humans</topic><topic>Hydroxychloroquine</topic><topic>Hydroxychloroquine - therapeutic use</topic><topic>Immunology</topic><topic>Immunosuppressive agents</topic><topic>Kidneys</topic><topic>Lupus</topic><topic>Lupus Erythematosus, Cutaneous - blood</topic><topic>Lupus Erythematosus, Cutaneous - drug therapy</topic><topic>Lupus Erythematosus, Systemic - blood</topic><topic>Lupus Erythematosus, Systemic - drug therapy</topic><topic>Lupus Nephritis - blood</topic><topic>Lupus Nephritis - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Retrospective Studies</topic><topic>S100 protein</topic><topic>Serum levels</topic><topic>Severity of Illness Index</topic><topic>Skin</topic><topic>Systemic lupus erythematosus</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wakiya, R</creatorcontrib><creatorcontrib>Kameda, T</creatorcontrib><creatorcontrib>Ueeda, K</creatorcontrib><creatorcontrib>Nakashima, S</creatorcontrib><creatorcontrib>Shimada, H</creatorcontrib><creatorcontrib>Mansour, M F</creatorcontrib><creatorcontrib>Kato, M</creatorcontrib><creatorcontrib>Miyagi, T</creatorcontrib><creatorcontrib>Miyatake, N</creatorcontrib><creatorcontrib>Kadowaki, N</creatorcontrib><creatorcontrib>Dobashi, H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Lupus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wakiya, R</au><au>Kameda, T</au><au>Ueeda, K</au><au>Nakashima, S</au><au>Shimada, H</au><au>Mansour, M F</au><au>Kato, M</au><au>Miyagi, T</au><au>Miyatake, N</au><au>Kadowaki, N</au><au>Dobashi, H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hydroxychloroquine modulates elevated expression of S100 proteins in systemic lupus erythematosus</atitle><jtitle>Lupus</jtitle><addtitle>Lupus</addtitle><date>2019-06-01</date><risdate>2019</risdate><volume>28</volume><issue>7</issue><spage>826</spage><epage>833</epage><pages>826-833</pages><issn>0961-2033</issn><eissn>1477-0962</eissn><abstract>Objectives
We investigated the effect of hydroxychloroquine (HCQ) on S100A8 and S100A9 serum levels in systemic lupus erythematosus (SLE) patients with low disease activity receiving immunosuppressants.
Methods
SELENA-SLEDAI, Cutaneous Lupus Erythematous Disease Area and Severity Index (CLASI) and serum levels of complement factors, anti-dsDNA antibodies, and white blood cell, lymphocyte, and platelet counts were used to evaluate disease activity, cutaneous disease activity, and immunological activity, respectively. Serum S100A8 and S100A9 were measured at HCQ administration and after 3 or 6 months using ELISA.
Results
S100A8 and S100A9 serum levels were elevated at baseline and the magnitude of decrease from baseline at 3 and 6 months after HCQ administration was greater in patients with renal involvement than in those without (baseline: S100A8, p = 0.034; S100A9, p = 0.0084; decrease: S100A8, p = 0.049; S100A9, p = 0.023). S100 modulation was observed in patients with (n = 17; S100A8, p = 0.0011; S100A9, p = 0.0002) and without renal involvement (n = 20; S100A8, p = 0.0056; S100A9, p = 0.0012), and was more apparent in patients with improved CLASI activity scores (improved: S100A8, p = 0.013; S100A9, p = 0.0032; unimproved: S100A8, p = 0.055; S100A9, p = 0.055). No associations were observed for immunological biomarkers.
Conclusion
HCQ may improve organ involvement in SLE by modulating S100 protein levels, especially in patients with renal or skin involvement.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>31068068</pmid><doi>10.1177/0961203319846391</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-1998-548X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0961-2033 |
| ispartof | Lupus, 2019-06, Vol.28 (7), p.826-833 |
| issn | 0961-2033 1477-0962 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2231939211 |
| source | MEDLINE; SAGE Complete |
| subjects | Adult Anti-DNA antibodies Antirheumatic Agents - therapeutic use Biomarkers - blood Calgranulin A - blood Calgranulin B - blood Enzyme-linked immunosorbent assay Female Humans Hydroxychloroquine Hydroxychloroquine - therapeutic use Immunology Immunosuppressive agents Kidneys Lupus Lupus Erythematosus, Cutaneous - blood Lupus Erythematosus, Cutaneous - drug therapy Lupus Erythematosus, Systemic - blood Lupus Erythematosus, Systemic - drug therapy Lupus Nephritis - blood Lupus Nephritis - drug therapy Male Middle Aged Retrospective Studies S100 protein Serum levels Severity of Illness Index Skin Systemic lupus erythematosus Treatment Outcome |
| title | Hydroxychloroquine modulates elevated expression of S100 proteins in systemic lupus erythematosus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T13%3A07%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hydroxychloroquine%20modulates%20elevated%20expression%20of%20S100%20proteins%20in%20systemic%20lupus%20erythematosus&rft.jtitle=Lupus&rft.au=Wakiya,%20R&rft.date=2019-06-01&rft.volume=28&rft.issue=7&rft.spage=826&rft.epage=833&rft.pages=826-833&rft.issn=0961-2033&rft.eissn=1477-0962&rft_id=info:doi/10.1177/0961203319846391&rft_dat=%3Cproquest_cross%3E2231939211%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2239135523&rft_id=info:pmid/31068068&rft_sage_id=10.1177_0961203319846391&rfr_iscdi=true |